Eugène Cox

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Targeting hypoxia in cancer therapy

The role of JAK/STAT signaling pathway and its inhibitors in diseases

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001

Erectile Dysfunction and Lower Urinary Tract

Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting

Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

The JAK/STAT signaling pathway: from bench to clinic

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

Ulcerative colitis

Diagnosing Model Diagnostics

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis

Clinical Practice Guideline: Sudden Hearing Loss (Update)

Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

Dose translation from animal to human studies revisited

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Enhancement of transdermal delivery of phenylbutazone from liposomal gel formulations through deer skin

Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9

A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron

Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra®)

Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Synthetic Opioids in the Rat: Correlation with the Interaction at the Mu-Opioid Receptor

Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)